Compare TG Therapeutics Inc (TGTX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Yum China Holdings Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Yum China Holdings Inc trades at $43.91 (market cap $15.09B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.64% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | YUMC | |
|---|---|---|
Market Cap | $8.26B | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $57.95 |
52-Week Low | $26.39 | $40.18 |
Enterprise Value | $8.50B | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
YUMC trades at $42.77, down 2.51% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows consistent revenue growth, reaching $11.80B in 2025, and has beaten earnings estimates in three consecutive quarters. Recent strategic moves include the acquisition of Pizza Hut China, enhancing local control and cost synergies. Analyst sentiment remains strongly positive with 14 buy ratings and no sell recommendations.
The outlook for YUMC is favorable due to solid fundamentals and strategic initiatives, though risks include macroeconomic headwinds in China and competitive pressures. Valuation metrics like a P/E of 16.83 and EV/EBITDA of 8.76 suggest reasonable pricing relative to earnings, supporting potential upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
